Healthcare provider profile · identity verified

Mark P Bishop, MD

Family Practice · MINERAL POINT, WI · NPI 1659366508

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	292	68
Synthroid	Levothyroxine Sodium	279	61
Lisinopril	Lisinopril	208	49
Amlodipine Besylate	Amlodipine Besylate	191	51
Albuterol Sulfate Hfa	Albuterol Sulfate	183	47
Potassium Chloride	Potassium Chloride	160	37
Losartan Potassium	Losartan Potassium	158	35
Ozempic	Semaglutide	154	34
Gabapentin	Gabapentin	143	33
Jardiance	Empagliflozin	139	26
Fluticasone Propionate	Fluticasone Propionate	127	36
Eliquis	Apixaban	121	24
Omeprazole	Omeprazole	114	32
Furosemide	Furosemide	107	27
Simvastatin	Simvastatin	99	20
Metoprolol Succinate	Metoprolol Succinate	94	24
Metformin Hcl	Metformin Hcl	89	20
Metformin Hcl Er	Metformin Hcl	82	18
Clopidogrel	Clopidogrel Bisulfate	78	17
Terazosin Hcl	Terazosin Hcl	76	16
Pantoprazole Sodium	Pantoprazole Sodium	72	14
Spiriva Respimat	Tiotropium Bromide	71	16
Rosuvastatin Calcium	Rosuvastatin Calcium	70	22
Diclofenac Sodium	Diclofenac Sodium	67	25
Wixela Inhub	Fluticasone Propion/Salmeterol	66	21
Fluoxetine Hcl	Fluoxetine Hcl	62	12
Allopurinol	Allopurinol	59	14
Carvedilol	Carvedilol	59	14
Hydroxyzine Hcl	Hydroxyzine Hcl	58	16
Metoprolol Tartrate	Metoprolol Tartrate	53	15
Finasteride	Finasteride	52	13
Sertraline Hcl	Sertraline Hcl	52	14
Glipizide Er	Glipizide	51	14
Trazodone Hcl	Trazodone Hcl	51	13
Montelukast Sodium	Montelukast Sodium	50	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	47	suppressed
Alendronate Sodium	Alendronate Sodium	44	suppressed
Ibuprofen	Ibuprofen	39	13
Amitriptyline Hcl	Amitriptyline Hcl	37	suppressed
Entresto	Sacubitril/Valsartan	36	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	35	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	33	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	33	suppressed
Spironolactone	Spironolactone	32	12
Estradiol	Estradiol	30	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	29	suppressed
Ezetimibe	Ezetimibe	28	suppressed
Hydralazine Hcl	Hydralazine Hcl	26	suppressed
Clonidine Hcl	Clonidine Hcl	25	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	suppressed
Atenolol	Atenolol	22	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	20	11
Corlanor	Ivabradine Hcl	20	suppressed
Invega Sustenna	Paliperidone Palmitate	20	suppressed
Xarelto	Rivaroxaban	20	suppressed
Glipizide Xl	Glipizide	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Meloxicam	Meloxicam	18	suppressed
Novolog Flexpen	Insulin Aspart	18	11
Pioglitazone Hcl	Pioglitazone Hcl	18	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Folic Acid	Folic Acid	17	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	17	suppressed
Naproxen	Naproxen	16	suppressed
Prednisone	Prednisone	16	suppressed
Ranolazine Er	Ranolazine	16	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	13	suppressed
Latanoprost	Latanoprost	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Alogliptin	Alogliptin Benzoate	12	suppressed
Aripiprazole	Aripiprazole	12	suppressed
Baclofen	Baclofen	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Duloxetine Hcl	Duloxetine Hcl	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Metronidazole	Metronidazole	11	suppressed
Minocycline Hcl	Minocycline Hcl	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Primidone	Primidone	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error